Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,801–1,900 of 3,704
Ezenekwe, L., & Newberry, C. A. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.70074 · Cited by 3
“60 The risk of muscle loss with GLP ‐ 1RAs is likely outweighed by the well ‐ documented health benefits.”
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
“By effectively decreasing HbA1c levels and supporting weight loss, tirzepatide aids in preventing cardiovascular complications, nephrotoxicity, and neurotoxicity, which are key contributors to recurrent hospitalization and escalating healthcare costs.”
Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea
Noreña, J. A., Akcan, T., & Desai, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000949 · Cited by 3
New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report
Purvez, A., Mirza, M., & Bashir, M. (2025) · Cureus · doi:10.7759/cureus.99651 · Cited by 3
“Improvements in blood pressure, inflammatory markers, and lipid profiles accompany these effects, indicating a broad cardiometabolic benefit [5-7].”
Incretin-Based Therapies and Post–Bariatric Surgery Alcohol Use Disorder
Fakhoury, B., Sierra, L., Rama, K., Jahagirdar, V., Díaz, L. A., & Arab, J. P. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.49086 · Cited by 6
Translational Lifestyle Medicine Approaches to Cardiovascular–Kidney–Metabolic Syndrome
Papadakis, Z. (2025) · Healthcare · doi:10.3390/healthcare14010051 · Cited by 8
“However, there is uncertainty regarding how these agents interact with individual or combined components of the six pillars of lifestyle medicine [61,96,98–101].”
El‐Amawy, H. S. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501255 · Cited by 12
Alam, A. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_164_25 · Cited by 3
AlQarni, B. S., Aldadi, S., & Alotaibi, A. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102485 · Cited by 3
Young, C. B., Rives, E., Gudzune, K. A., Jaeger, B. C., Simmons, C., White, B. N., Hooker, S. A., Horn, D. B., Young, D. R., Vesely, J. M., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108219 · Cited by 4
Adapa, S., Fahey, P. P., Piya, M. K., Birhanu, F., & Atlantis, E. E. (2026) · Obesity Reviews · doi:10.1111/obr.70091 · Cited by 3
“Weight loss also led to significant improvements in mean lipid profiles, with groups achieving ≥ 5%TWL showing reductions in mean triglycerides and increases in mean HDL-cholesterol, both favorable changes [67, 73, 77].”
Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice
Moura‐Assis, A., Plucińska, K., Meseguer, D., Baleisyte, A., Chen, B., Pellegrino, K., Parolari, L., Shaked, J. T., Page, K. J., Barrows, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68056-x · Cited by 4
Panunzi, S., Russo, S. L. M. L., Pompa, M., Gaetano, A. D., Verrastro, O., Tuccinardi, D., Guidone, C., Castagneto‐Gissey, L., Casella, G., Mariolo, J. R. C., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156495 · Cited by 6
Dâmaso, A. R., Corgosinho, F. C., Masquio, D. C. L., Figueiredo, N., Kattah, F. M., Cercato, C., Tock, L., & Campos, R. M. D. S. (2026) · Obesity Reviews · doi:10.1111/obr.70093 · Cited by 7
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“SURMOUNT 1 [99] compared tirzepatide 5 mg vs 10 mg vs 15 mg vs placebo in patients without diabetes.”
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“Three studies were treated with semaglutide (SME) [28–30], three with LIR [31–33], one with SME or LIR [34], one with oral semaglutide (OSM) [35], one with orforglipron (ORF) [36], two with tirzepatide (TZP) [37, 38] and one with retatrutide (RET) [39].”
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Management of the kidney transplant candidate with obesity
Abbasi, A. B., & Orandi, B. J. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001266 · Cited by 3
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
“Moreover, over 90% of overweight or obese patients who met the criteria for prediabetes reversed this carbohydrate metab‑ olism disorder [55].”
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
“…for the treatment of obesity in adult patients with a BMI of 30 or more or with a BMI of 27 or more with at least one weight-related complication excluding diabetes [75]; 2539 adults were assigned to once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks [75].”
InfluentialUnintended risks of sarcopenic obesity during weight-loss interventions in older people
Batsis, J. A., Donini, L. M., & Prado, C. M. M. (2026) · Nature Medicine · doi:10.1038/s41591-026-04210-2 · Cited by 5
Daggolu, J., & Chen, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70555 · Cited by 6
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Chadwick, J., Sivamani, C., Lakshmi, S., Vishali, B., Swathi, N. L., Ayyasamy, L., Ganeshkumar, P., & Bagepally, B. S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08508-5 · Cited by 5
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Laurence, A., Gandhi, S., Nylén, E., & Sen, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.011 · Cited by 3
Zufry, H., & Hariyanto, T. I. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.02.002 · Cited by 9
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
“The ef fi cacy of setmelanotide may not be suf fi cient for POMC-MC4R de fi cient patients because body weight reduction ratio of semaglutide and tirzepatide were 12.4 and 17.8%, respectively in clinical study as compared with that of setmelanotide, 5.2% [[18, 19, 23]].”
InfluentialSchmickl, C. N., Tripipitsiriwat, A., Mokhlesi, B., Mallampalli, M. P., Nokes, B. T., Kundel, V., Page, K., Finch, C. E., Donovan, L. M., Tadros, M., et al. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-025-00024-0 · Cited by 6
“Furthermore, in routine practice, tirzepatide adherence may fall short of the > 80% in the SURMOUNT trials [24 , 25 ].”
InfluentialSelf-citationRedefining Obstructive Sleep Apnea: Treatment in the Modern Era
Redondo, J., Ascher, K. B., & Abreu, A. R. (2026) · Pathophysiology · doi:10.3390/pathophysiology33010020 · Cited by 4
Discontinuation of incretin-based therapies in obesity: the complexity of a breakup
Avogaro, A., & Fadini, G. P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106833 · Cited by 6
Sridhar, A., Palmer, E. S., Craig, S. L., Krason‐Kidzinska, E., Irwin, N., & O'Harte, F. P. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70647 · Cited by 3
Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
Old, V. J., Davies, M. J., Denniff, M. J., Choudhary, P., Eastley, N. C., Ashford, R. U., & Watson, E. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70254 · Cited by 6
“Initially developed for glycaemic control in T2DM, GLP-1RAs have since been approved for weight loss, showing 10%–15% reductions in total body weight with semaglutide [2, 3] and 15%–20% with dual agonist tirzepatide [4, 5].”
Aronne, L. J., Horn, D. B., Kokkinos, A. D., Falcón, B. L., Wang, H., Hoffmann, H. T., Lee, C. J., & Dunn, J. P. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.010 · Cited by 6
Self-citationBarazzoni, R., Ballesteros-Pomar, M. D., Bischoff, S. C., Blaauw, R., Boirie, Y., Carey, S., Cederholm, T., Cortés, Y., Cuerda, C. G., Deutz, N. E. P., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106645 · Cited by 8
“…incretin-based anti-obesity medications (AOM) lead to substantial weight loss above 15 – 20%, and increasing AOM utilization may increase the risk of sarcopenic obesity, with subgroup analyses showing that one-quarter to one-third of lost weight is attributable to lean tissues [15,16,18,19].”
Improving incretin-mediated body weight loss via energy expenditure
Elmendorf, A. J., Douros, J. D., Knerr, P. J., & Flak, J. N. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.12.004 · Cited by 5
Standen, E. C., Phelan, S. M., & Tomiyama, A. J. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02061-y · Cited by 12
“Evidence suggests that these new GLP-1s are effective for achieving clinically signi fi cant weight loss [4 – 6], although long-term follow-up studies are still needed [7].”
Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Lim, M. W., Gokhale, P., Akosah, A. A., & Zapata, L. V. (2026) · Obesity · doi:10.1002/oby.70169 · Cited by 6
“In trials that reported race, a majority of the participants were White, ranging from 70% in Jastreboff et al. [30] to 90% in McGowan et al. [25].”
Wu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Li, Q., Cheng, W., Zhang, L., Ran, S., Yu, H., Zhou, W., Wang, Y., Lin, J., Liu, Y., Hong, X., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02116-0 · Cited by 5
“Incretin-based pharmacotherapies have revolutionized obesity treatment, beginning with GLP-1 receptor agonists such as semaglutide and extending to dual GIP/ GLP-1 agonists like tirzepatide [26, 27].”
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Menezes, L. A., Helena Dos Santos, R. E. I. S., de Souza, M. A. A., et al. (2026) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.66104/qc09as49 · Cited by 3
Iorra, F. D. Q., Jayakar, T., Yee, M. S., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026) · Liver International · doi:10.1111/liv.70643 · Cited by 9
“Landmark trials such as STEP-1 (semaglutide) [36], SUSTAIN-8 (semaglutide) [37], and SURMOUNT-1 (tirzepatide) [38] offer contextual support for this estimate.”
Murugadoss, K., Varma, G., Venkatakrishnan, A., Gibson, M. C., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag020 · Cited by 11
Angelopoulos, N., Zianni, D., Livadas, S., Androulakis, I., Fousteris, E., Paparodis, R. D., Petkova, V., Florakis, D., Mouslech, Z., Rizoulis, A. A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70810 · Cited by 6
“This aligns with the concept—supported by trial data—that clinically relevant weight loss can occur across a wide baseline BMI range, and it strengthens external validity by implying applicability across obesity severity categories [4, 8].”
InfluentialIncretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 6
“In the weight-management program, the proportion of female participants with preexisting PCOS at baseline was 0.2% in SURMOUNT-1, 1.0% in SURMOUNT-2, 4.4% in SUR-MOUNT-3, and 4.9% in SURMOUNT-4 [68–71].”
InfluentialZambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
“…important therapeutic space between lifestyle intervention and surgery: they can achieve substantial weight loss during active treatment, but their real-world impact depends on tolerability, persistence, nutritional adequacy, body-composition monitoring, and long-term maintenance planning [7,9,16].”
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Weight-loss dynamics with tirzepatide versus semaglutide
Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · PNAS Nexus · doi:10.1093/pnasnexus/pgag171 · Cited by 10
“Third, this study did not assess dose escalation trajectories, including maximum dose achieved and duration of therapy, which have been shown to impact weight-loss magnitude in randomized trials and real-world studies from our group and others (3, 18, 19).”
InfluentialSimancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“Across these trials, mean weight reductions ranged from approximately 15% to more than 22% of baseline body weight [18,21,23,24].”
Jobanputra, R., Sargeant, J. A., Plekhanova, T., James, E., Almaqhawi, A., Webb, D. R., Davies, M. J., & Yates, T. E. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70194 · Cited by 11
“In addition, the latest dual agonist weight loss therapies were also not included due to a lack of complete body composition data within the main trial population [66].”
Naik, H. B., & Thiara, D. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1882 · Cited by 3
Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes
Hamad, C. D., Wiener, J., Golzar, A., Hp, K., Henein, C., Kittredge, A. P., Su, G., Kaelber, D. C., Chan, L., Yeaman, M. R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.25141 · Cited by 7
Goud, V. M., Sirisha, P., N, R. K., Godela, R., & Prasad, B. D. (2023) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.14.2.27 · Cited by 4
Jiang, P., Sun, N., Yang, W. Y., Xiao, L., Zhou, L., Gu, B., Li, Y., Li, L., Li, J., Li, X., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15235 · Cited by 3
Drug approach to treatment for obesity in adults: perspectives and considerations
Escalada, J. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10206/2023 · Cited by 3
Wachiraphansakul, N., Vongchaiudomchoke, T., Manosroi, W., & Nochaiwong, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297488 · Cited by 3
“Tirzepatide—a dual action, once-weekly GIP/GLP1-RA, also revealed significant weight loss in obese patients with or without type 2 diabetes [40, 41].”
InfluentialBauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 4
Wong, N. D., Karthikeyan, H., & Fan, W. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07583-z · Cited by 3
“We then applied the risk factor changes from the SURMOUNT-1 trial tirzepatide 15 mg group (as shown in Table S4 in the Appendix of the SURMOUNT-1 publication [11]) to estimate the “post-treatment” 10-year CVD risk similarly with these equations.”
InfluentialHamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
“Therefore, various strategies to enhance the incretin effect have been developed for T2D treatment (4, 12 – 15).”
BackgroundCarmo‐Silva, S., & Nóbrega, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-62491-9_2 · Cited by 3
Talay, L., Vickers, M., & Alvi, O. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15903 · Cited by 4
“17,18 Results from these RCT series also indicate that tirzepatide's safety profile may be slightly better than that of semaglutide.”
Heald, A. H., Stedman, M., Warner-Levy, J. J., Whyte, M., Rutter, M. K., & Gibson, M. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000310 · Cited by 3
“…found that in people with over-weight/obese but without diabetes, 72 weeks of the combined GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist, tirzepatide, at doses of 5, 10, or 15 mg led to 15.0, 19.5, and 20.9% weight loss, respectively, compared with 3.1% in people taking placebo [9].”
ResultInfluentialRetinoids and retinoid-binding proteins: Unexpected roles in metabolic disease
Blaner, W. S., Paik, J., Brun, P., & Golczak, M. (2024) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2024.10.001 · Cited by 5
Koutroumpakis, E., Venkatesh, N., Aparicio, A. M., Song, J., Panaretakis, T., Deswal, A. M., Logothetis, C. J., Frigo, D. E., & Hahn, A. W. (2024) · The Oncologist · doi:10.1093/oncolo/oyae308 · Cited by 4
“44,45 Finally, based on the results of our study, serum leptin levels could also be used as a marker for patient risk stratification and personalization of prostate cancer treatment by guiding preventive cardiovascular therapies such as statins.”
Semaglutide vs Tirzepatide Dosages for Weight Loss
Levy, M. E., Barrett, K. M. S., & Cirulli, E. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5768 · Cited by 4
Generalizability of clinical trials of novel weight loss medications to the US adult population
Bessette, L. G., & Anderson, T. S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.6340 · Cited by 4
Foutz, M. A., Krinos, E. L., Beretta, M., Hargett, S. R., Shrestha, R., Murray, J. H., Duerre, E., Salamoun, J. M., McCarter, K., Shah, D. P., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02366 · Cited by 5
An Evaluation of Primary Care Clinician Referrals for Behavioral Weight Loss Counseling
Saraiya, V., Berkowitz, S. A., Johnston, L. F., Couper, D. J., Sotres‐Alvarez, D., Lyons, K. M., Thaxton, C. K., Skinner, H. G., Samuel‐Hodge, C. D., & Keyserling, T. C. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241308054 · Cited by 3
Takyi, A. K., Gaffey, R. H., & Shukla, A. P. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00465-1 · Cited by 4
“Tirzepatide also led to improvements in cardiometabolic risk factors [27–30]. d. Side effects: In the SURMOUNT-1 and 4 trials, participants taking up to tirzepatide 15 mg experienced gastro-intestinal symptoms, including nausea (31.0%-35.5%), diarrhea (21.1%-23%), constipation (11.7%-20.7%), and…”
InfluentialEndoscopic Weight Loss Options
Bi, D., & Jirapinyo, P. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.11.002 · Cited by 3
Do weight loss interventions challenge the obesity paradox in heart failure?
Yurista, S. R., Eder, R. A., Butsch, W. S., & Luptak, I. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.006 · Cited by 5
A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use
Lam, C. Y., Lin, D., & Endlich, Y. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x241311597 · Cited by 5
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
Incretin mimetics for weight loss forgive nonadherence
Cengiz, A., Wu, C. C., & Lawley, S. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16438 · Cited by 4
“7,8,26 To elaborate, the standard dosing regimens of these incretin mimetics appear to be at the top end of a saturating dose – response curve, meaning that increasing or decreasing the dose does not proportionately affect weight loss.”
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone
Ferrara, F., Bazzani, D., Crivelli, B., Danieli, E., Gazzola, P., Guarnieri, G., Handschin, G., Lauria, C., Marchetti, C., Sbraga, E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04319-0 · Cited by 4
“Ongoing studies are investigating the combined use of semaglutide with other pharmacological agents, such as tirzepatide, which acts on both GLP-1 and GIP receptors and has shown even more encouraging preliminary results (Jastreboff et al. 2022).”
Animal Models of Exercise and Cardiometabolic Disease
Dong, G., RYAN, T. E., & Esser, K. A. (2025) · Circulation Research · doi:10.1161/circresaha.124.325704 · Cited by 6
Arai, T., Atsukawa, M., Nagao, C., Yamada, Z., Rokugo, T., Suzuki, K. M., Kitamura, M., Higashi, T., Koyano, K., Hasegawa, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14241 · Cited by 8
Dowgiałło‐Gornowicz, N., Wityk, M., Jaworski, P., Lech, P., & Parmar, C. D. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08026-w · Cited by 3
“Tirzepatide appears to be a promising option for older adults, as its side effect profile is improved [29].”
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Advances in postpartum hypertension management: a review of current guidelines and interventions
McCoy, S. E., Hurwitz, M., Kwapong, Y. A., Bircan, E., Spitz, J. A., Dastmalchi, L. N., Metlock, F., Saad, A. F., Sarma, A. A., Khandelwal, A., et al. (2025) · npj Women s Health · doi:10.1038/s44294-025-00095-7 · Cited by 11
Colorado, M., Miranda, J. G., & Arias-Morales, C. E. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf195 · Cited by 3
“The overall safety findings in both trials highlight the tolerability of tirzepatide, with gastrointestinal side effects being the most common and generally mild to moderate [7].”
Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study
Aggarwal, R., Nicholls, S. J., D’Alessio, D. A., & Bhatt, D. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.08.009 · Cited by 3
O EFEITO DOS ANÁLOGOS DE GLP1 NA MASLD: MECANISMOS, EVIDÊNCIAS E PERSPECTIVAS
Prudente, L. L., de Oliveira, G. A. M., & Cardoso, M. A. P. (2025) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/t9z40s73 · Cited by 3
Mitkin, N. A., Pavshintsev, V. V., Sukhanova, I. A., Doronin, I. I., Babkin, G. A., Sadagurski, M., & Malyshev, A. V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102088 · Cited by 5
“There are several Food and Drug Administration (FDA)-approved treatments for T2D, including the first-line treatment metformin (Glucophage) [18] and the novel drug tirzepatide (Mounjaro) [19], a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [20,21].”
BackgroundFernández, M. G. M., Chamik, E. R. T., Rivera, V. M. L., Delgado, M. C. R., Feijoó, A. C. S., & Aguinsaca, K. F. P. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i1.4596 · Cited by 8
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
Current pharmacological approaches in obesity treatment
TİRYAKİOĞLU, P., Yilmaz, H., Demir, İ., & Yilmaz, I. C. (2023) · DAHUDER Medical Journal · doi:10.56016/dahudermj.1271677 · Cited by 5
Shin, W., Hompesch, M., Byeon, J., Kang, S., Choi, J., & Baek, S. J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15162 · Cited by 3
Barber, T. M. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-143 · Cited by 3
“We are at the dawn of a sea-change in our therapeutic armamentarium for obesity management, with the recent launch of tirzepatide as a dual glucagon-like peptide-1 (GLP1) and gastric inhibitory polypeptide (GIP) incretin agonist, and multiple other incretin and intestinal polypeptide agonist therapies in development (…”
BackgroundSURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Frandsen, C. S., & Madsbad, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01292-8 · Cited by 3
Updates in the Treatment of Pediatric Obesity
Wright, T. F., Rivero, C. M., & Barlow, S. E. (2023) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-023-00270-5 · Cited by 3
“This medication is a combination of glucose dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, adult studies of 5 mg, 10 mg, and 15 mg weekly subcutaneous injections show 19 to 20% reduction in weight with the two higher doses [23].”
BackgroundAre GLP-1R agonists the long-sought-after panacea for obesity?
Dowsett, G. K. C., & Yeo, G. S. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.06.008 · Cited by 6
Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs
Ahmad, B. A., Sanghani, I. M., Sayabugari, R., Biju, H., Siddegowda, A., Kinattingal, M. I., Yartha, S. G. R., Gaonkar, P. M., Andrabi, S. S., Vaghamashi, Y., et al. (2023) · Cureus · doi:10.7759/cureus.46373 · Cited by 5
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 4
Issa, D. (2023) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2023.08.016 · Cited by 3
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
Zhu, J., & Wilding, J. P. H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01181-4 · Cited by 4
“…mg), body weight reduction from baseline was 15%, 20%, 21% and mean depletion ratio (for all doses) of fat to lean body mass was 3 after 72 weeks [90]; in patients with T2DM with BMI ranging from 33.1 to 34.5 kg/m 2 , tirzepatide (5, 10, 15 mg) was associated with 23 to 38% and 21 to 29% of fat…”
InfluentialRevolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Sood, A., Kaur, P., Syed, O., Sood, A., Aronow, W. S., Borokhovsky, B., Bhatia, V., & Gupta, R. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2310070 · Cited by 4
“A p r i l 2022 [ 27 ] ( N = 2539 ) ● P a t i e n t s m u s t H a v e a B M I o f ≥ 27 k g / m 2 .”
BackgroundInfluential
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.